Skip NavigationSkip to Content
Return Return to Search Results

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

  1. Author:
    Boyd, S. D.
    Maldarelli, F.
    Sereti, I.
    Ouedraogo, G. L.
    Rehm, C. A.
    Boltz, V.
    Shoemaker, D.
    Pau, A. K.

  2. Author Address

    [Boyd, SD; Sereti, I; Ouedraogo, GL; Rehm, CA; Shoemaker, D; Pau, AK] NIAID, NIH, Bethesda, MD 20892 USA. [Boyd, SD; Ouedraogo, GL] SAIC Frederick Inc, Frederick, MD USA. [Maldarelli, F; Boltz, V] NCI, HIV Drug Resistance Program, NIH, Bethesda, MD 20892 USA.;Boyd, SD (reprint author), US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA;sarita.boyd@fda.hhs.gov
    1. Year: 2011
  2. Journal: Antiviral Therapy
    1. 16
    2. 2
    3. Pages: 257-261
  4. Type of Article: Article
  5. ISSN: 1359-6535
  1. Abstract:

    Here, we describe an HIV-infected patient with pretreatment resistance to raltegravir, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, and the ultimate ability to achieve viral suppression. Pretreatment integrase resistance testing is not routinely performed because transmitted integrase mutations conferring resistance to raltegravir are currently thought to be negligible. We suggest obtaining a pretreatment integrase genotype in patients with transmitted multiclass drug resistance in order to create an optimal first regimen and increase the chance for virological suppression.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.3851/imp1749
  3. View record in Web of Science®
  4. WOS: 000294375500017

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel